Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells

Biochimie

Volumn 94, Issue 6, 2012, Pages 1382-1389

  Lee, Che Hsin ^a   Hong, Hui Mei ^b,c   Chang, Yu Ying ^b   Chang, Wen Wei ^b,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Breast cancer stem cells; Heat shock protein; Hsp27; Hsp90

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; GELDANAMYCIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90 INHIBITOR; HERMES ANTIGEN; KNK 437; QUERCETIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER STEM CELL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS;

ALDEHYDE DEHYDROGENASE; BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GENE SILENCING; HSP27 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASTIC STEM CELLS; UP-REGULATION;

EID: 84860428721     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.02.034     Document Type: Article

References (41)

1. C. Georgopoulos, and W.J. Welch Role of the major heat shock proteins as molecular chaperones Annu. Rev. CellBiol. 9 1993 601 634
2. E.T. Soo, G.W. Yip, Z.M. Lwin, S.D. Kumar, and B.H. Bay Heat shock proteins as novel therapeutic targets in cancer In Vivo (Athens, Greece) 22 2008 311 315
3. A.S. Sreedhar, E. Kalmar, P. Csermely, and Y.F. Shen Hsp90 isoforms: functions, expression and clinical importance FEBS Letters 562 2004 11 15 (Pubitemid 38388440)
4. M.A. Brown, L. Zhu, C. Schmidt, and P.W. Tucker Hsp90-from signal transduction to cell transformation Biochem. Biophysical Research Communications 363 2007 241 246 (Pubitemid 47484324)
5. A. Jameel, R.A. Skilton, T.A. Campbell, S.K. Chander, R.C. Coombes, and Y.A. Luqmani Clinical and biological significance of HSP89 alpha in human breast cancer Int. J. Cancer 50 1992 409 415
6. P.N. Munster, M. Srethapakdi, M.M. Moasser, and N. Rosen Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells Cancer Res. 61 2001 2945 2952 (Pubitemid 32691939)
7. S. Modi, A.T. Stopeck, M.S. Gordon, D. Mendelson, D.B. Solit, R. Bagatell, W. Ma, J. Wheler, N. Rosen, L. Norton, G.F. Cropp, R.G. Johnson, A.L. Hannah, and C.A. Hudis Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study J. Clin. Oncol. 25 2007 5410 5417 (Pubitemid 350232217)
8. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M.A. Caligiuri, and J.E. Dick A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 1994 645 648 (Pubitemid 24067706)
9. P. Dalerba, R.W. Cho, and M.F. Clarke Cancer stem cells: models and concepts Annu. Rev. Med. 58 2007 267 284 (Pubitemid 46706514)
10. M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke Prospective identification of tumorigenic breast cancer cells Proc. Natl. Acad. Sci. U S A 100 2003 3983 3988 (Pubitemid 36418143)
11. C. Ginestier, M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha, and G. Dontu ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 1 2007 555 567 (Pubitemid 350056407)
12. T.M. Phillips, W.H. McBride, and F. Pajonk The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation J. Natl. Cancer Inst. 98 2006 1777 1785 (Pubitemid 46017929)
13. M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. McNamara, R.H. Datar, and R.J. Cote Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype Clin. Cancer Res. 12 2006 5615 5621 (Pubitemid 44629587)
14. S.A. Mani, W. Guo, M.J. Liao, E.N. Eaton, A. Ayyanan, A.Y. Zhou, M. Brooks, F. Reinhard, C.C. Zhang, M. Shipitsin, L.L. Campbell, K. Polyak, C. Brisken, J. Yang, and R.A. Weinberg The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133 2008 704 715 (Pubitemid 351636299)
15. R.K. Ramanathan, M.J. Egorin, C. Erlichman, S.C. Remick, S.S. Ramalingam, C. Naret, J.L. Holleran, C.J. TenEyck, S.P. Ivy, and C.P. Belani Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17- demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors J. Clin. Oncol. 28 2010 1520 1526
16. W.W. Chang, C.H. Lee, P. Lee, J. Lin, C.W. Hsu, J.T. Hung, J.J. Lin, J.C. Yu, L.E. Shao, J. Yu, C.H. Wong, and A.L. Yu Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis Proc. Natl. Acad. Sci. U S A 105 2008 11667 11672
17. L. Wei, T.T. Liu, H.H. Wang, H.M. Hong, A.L. Yu, H.P. Feng, and W.W. Chang Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-kappa B Breast Cancer Res. 13 2011 R101
18. M.V. Powers, and P. Workman Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors Endocrine-related Cancer 13 Suppl. 1 2006 S125 S135
19. J. Zhou, J. Wulfkuhle, H. Zhang, P. Gu, Y. Yang, J. Deng, J.B. Margolick, L.A. Liotta, E. Petricoin 3rd, and Y. Zhang Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance Proc. Natl. Acad. Sci. U S A 104 2007 16158 16163 (Pubitemid 350099378)
20. D. Mahalingam, R. Swords, J.S. Carew, S.T. Nawrocki, K. Bhalla, and F.J. Giles Targeting HSP90 for cancer therapy Br. J. Cancer 100 2009 1523 1529
21. E.L. Davenport, A. Zeisig, L.I. Aronson, H.E. Moore, S. Hockley, D. Gonzalez, E.M. Smith, M.V. Powers, S.Y. Sharp, P. Workman, G.J. Morgan, and F.E. Davies Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma Leukemia 24 2010 1804 1807
22. A.K. McCollum, C.J. Teneyck, B.M. Sauer, D.O. Toft, and C. Erlichman Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism Cancer Res. 66 2006 10967 10975 (Pubitemid 44876996)
23. D. Ponti, A. Costa, N. Zaffaroni, G. Pratesi, G. Petrangolini, D. Coradini, S. Pilotti, M.A. Pierotti, and M.G. Daidone Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties Cancer Res. 65 2005 5506 5511 (Pubitemid 40911148)
24. C. Garrido, M. Brunet, C. Didelot, Y. Zermati, E. Schmitt, and G. Kroemer Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties Cell Cycle 5 2006 2592 2601 Georgetown, Tex (Pubitemid 44785803)
25. R.K. Hansen, S. Oesterreich, P. Lemieux, K.D. Sarge, and S.A. Fuqua Quercetin inhibits heat shock protein induction but not heat shock factor DNA-binding in human breast carcinoma cells Biochem. Biophysical Research Communications 239 1997 851 856 (Pubitemid 27504191)
26. M. Koishi, S. Yokota, T. Mae, Y. Nishimura, S. Kanamori, N. Horii, K. Shibuya, K. Sasai, and M. Hiraoka The effects of KNK437, a novel inhibitor of heat shock protein synthesis, on the acquisition of thermotolerance in a murine transplantable tumor in vivo Clin. Cancer Res. 7 2001 215 219 (Pubitemid 32110226)
27. H.R. Seo, D.Y. Chung, Y.J. Lee, D.H. Lee, J.I. Kim, S. Bae, H.Y. Chung, S.J. Lee, D. Jeoung, and Y.S. Lee Heat shock protein 25 or inducible heat shock protein 70 activates heat shock factor 1: dephosphorylation on serine 307 through inhibition of ERK1/2 phosphorylation J. Biol. Chem. 281 2006 17220 17227
28. J.P. Grenert, W.P. Sullivan, P. Fadden, T.A. Haystead, J. Clark, E. Mimnaugh, H. Krutzsch, H.J. Ochel, T.W. Schulte, E. Sausville, L.M. Neckers, and D.O. Toft The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation J. Biol. Chem. 272 1997 23843 23850 (Pubitemid 27410964)
29. M.V. Powers, and P. Workman Inhibitors of the heat shock response: biology and pharmacology FEBS Letters 581 2007 3758 3769 (Pubitemid 47081010)
30. R.S. Williams, and I.J. Benjamin Protective responses in the ischemic myocardium J. Clinical Investigation 106 2000 813 818
31. F. Guo, K. Rocha, P. Bali, M. Pranpat, W. Fiskus, S. Boyapalle, S. Kumaraswamy, M. Balasis, B. Greedy, E.S. Armitage, N. Lawrence, and K. Bhalla Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin Cancer Res. 65 2005 10536 10544 (Pubitemid 41743748)
32. C. Garrido, J.M. Bruey, A. Fromentin, A. Hammann, A.P. Arrigo, and E. Solary HSP27 inhibits cytochrome c-dependent activation of procaspase-9 Faseb J. 13 1999 2061 2070 (Pubitemid 29517636)
33. C.Y. Li, J.S. Lee, Y.G. Ko, J.I. Kim, and J.S. Seo Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation J. Biol. Chem. 275 2000 25665 25671
34. M.J. Rane, Y. Pan, S. Singh, D.W. Powell, R. Wu, T. Cummins, Q. Chen, K.R. McLeish, and J.B. Klein Heat shock protein 27 controls apoptosis by regulating Akt activation J. Biol. Chem. 278 2003 27828 27835 (Pubitemid 36899975)
35. R. Wu, H. Kausar, P. Johnson, D.E. Montoya-Durango, M. Merchant, and M.J. Rane Hsp27 regulates Akt activation and polymorphonuclear leukocyte apoptosis by scaffolding MK2 to Akt signal complex J. Biol. Chem. 282 2007 21598 21608 (Pubitemid 47195774)
36. J.G. Supko, R.L. Hickman, M.R. Grever, and L. Malspeis Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent Cancer Chemotherapy Pharmacology 36 1995 305 315
37. M.P. Goetz, D. Toft, J. Reid, M. Ames, B. Stensgard, S. Safgren, A.A. Adjei, J. Sloan, P. Atherton, V. Vasile, S. Salazaar, A. Adjei, G. Croghan, and C. Erlichman Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer J. Clin. Oncol. 23 2005 1078 1087 (Pubitemid 46202262)
38. G.S. Nowakowski, A.K. McCollum, M.M. Ames, S.J. Mandrekar, J.M. Reid, A.A. Adjei, D.O. Toft, S.L. Safgren, and C. Erlichman A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer Clin. Cancer Res. 12 2006 6087 6093 (Pubitemid 44703773)
39. J.E. Lancet, I. Gojo, M. Burton, M. Quinn, S.M. Tighe, K. Kersey, Z. Zhong, M.X. Albitar, K. Bhalla, A.L. Hannah, and M.R. Baer Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia Leukemia 24 2010 699 705
40. D.R. Ferry, A. Smith, J. Malkhandi, D.W. Fyfe, P.G. deTakats, D. Anderson, J. Baker, and D.J. Kerr Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition Clin. Cancer Res. 2 1996 659 668 (Pubitemid 26133468)
41. Z.P. Yuan, L.J. Chen, L.Y. Fan, M.H. Tang, G.L. Yang, H.S. Yang, X.B. Du, G.Q. Wang, W.X. Yao, Q.M. Zhao, B. Ye, R. Wang, P. Diao, W. Zhang, H.B. Wu, X. Zhao, and Y.Q. Wei Liposomal quercetin efficiently suppresses growth of solid tumors in murine models Clin. Cancer Res. 12 2006 3193 3199 (Pubitemid 43837369)